LURAP1L

Across TCGA pan-cancer cohorts, LURAP1L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LURAP1L data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher LURAP1L mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LURAP1L expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

LSCC, PDAC, and UCEC are the cancer types where LURAP1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	II,III,IV	0.610	1.000	.004	35	view →
PDAC	OS	Median	All	0.696	0.385	.003	28	view →
UCEC	DFS	Tertile	All	1.000	0.814	.003	16	view →
LUAD	DFS	Tertile	III,IV	0.338	0.709	.019	11	view →
CCRCC	DFS	Quartile	III,IV	0.878	0.414	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LURAP1L–LSCC (OS)

Open the LSCC breakdown →